Controlled document PF-013A
PLEXUS LUMBALIS Phase 1 Master Formula
TemplateDocumented
Record identification
- Document ID
- PF-013A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-013A
PRODUCT FORMULA CARD
SIRIAM PLEXUS LUMBALIS DUO – PHASE 1 (NERVE RELEASE)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PL-001 |
| MF-013 |
| PF-013A |
| PLEXUS LUMBALIS DUO – Phase 1 |
| L2–L4 |
| Nerve Release |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
ValueSIR-PL-001
ValueMF-013
ValuePF-013A
ValuePLEXUS LUMBALIS DUO – Phase 1
ValueL2–L4
ValueNerve Release
ValueTopical Magistral Cream
Value100 g
Value2.0
Value🔒 LOCKED
Value☐
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
| Description |
|---|
| Neurodermal modulation of the lumbar plexus |
| L2–L4 |
| Afferent unloading, psoas release and autonomic modulation |
| Phase 1 – Release |
| Topical Magistral Cream |
DescriptionNeurodermal modulation of the lumbar plexus
DescriptionL2–L4
DescriptionAfferent unloading, psoas release and autonomic modulation
DescriptionPhase 1 – Release
DescriptionTopical Magistral Cream
2. MASTER FORMULA
The ingredient quantities follow the uploaded Phase 1 magistral fiche, with the agreed SQMS standardisation.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| Fagron |
| 65.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| Fagron |
| 18.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| Fagron |
| 3.00 |
| g |
| W |
| SC-002 |
| MSM |
| — |
| 3.00 |
| g |
| W |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| Vitals |
| 2.00 |
| g |
| D |
| BE-001 |
| Boswellia serrata |
| WeightWorld |
| 1.00 |
| g |
| D |
| BE-013 |
| Solidago virgaurea (A.Vogel) |
| A.Vogel |
| 0.50 |
| mL |
| C |
| BE-009 |
| Ruta graveolens |
| — |
| 0.40 |
| mL |
| C |
| BE-008 |
| Arnica montana D6 |
| — |
| 0.50 |
| mL |
| C |
| BE-003 |
| Ginkgo biloba |
| Mattisson |
| 0.30 |
| g |
| C |
| BE-002 |
| Copaiba Oil |
| Aroma-Zone |
| 0.50 |
| mL |
| C |
| AC-002 |
| Betaine (TMG) |
| — |
| 0.80 |
| g |
| W |
| SC-003 |
| D-Panthenol |
| Natural Heroes |
| 0.80 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| Natural Heroes |
| 0.50 |
| g |
| L |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| — |
| 2.00 |
| g |
| C |
| CL-003 |
| Black Pepper CO₂ (optional) |
| — |
| 1 drop |
| C |
| PR-001 |
| Cosgard 221 |
| Aromantic |
| 0.70 |
| g |
| C |
CodeOfficial Ingredient
CodeSupplier
CodeMaster Qty
CodeUnit
CodePhase
CodePC-001
CodeLanette Cream FNA
CodeFagron
Code65.00
Codeg
CodeB
CodePC-002
CodeAqua Purificata
CodeFagron
Code18.00
Codeg
CodeW
CodeSC-001
CodeMagnesium Chloride
CodeFagron
Code3.00
Codeg
CodeW
CodeSC-002
CodeMSM
Code—
Code3.00
Codeg
CodeW
CodeAC-003
CodePalmitoylethanolamide (PEA)
CodeVitals
Code2.00
Codeg
CodeD
CodeBE-001
CodeBoswellia serrata
CodeWeightWorld
Code1.00
Codeg
CodeD
CodeBE-013
CodeSolidago virgaurea (A.Vogel)
CodeA.Vogel
Code0.50
CodemL
CodeC
CodeBE-009
CodeRuta graveolens
Code—
Code0.40
CodemL
CodeC
CodeBE-008
CodeArnica montana D6
Code—
Code0.50
CodemL
CodeC
CodeBE-003
CodeGinkgo biloba
CodeMattisson
Code0.30
Codeg
CodeC
CodeBE-002
CodeCopaiba Oil
CodeAroma-Zone
Code0.50
CodemL
CodeC
CodeAC-002
CodeBetaine (TMG)
Code—
Code0.80
Codeg
CodeW
CodeSC-003
CodeD-Panthenol
CodeNatural Heroes
Code0.80
Codeg
CodeW
CodeSC-004
CodeVitamin E Full Spectrum
CodeNatural Heroes
Code0.50
Codeg
CodeL
CodeSC-005
CodeSilicea Gel (+1 drop Silicea D8)
Code—
Code2.00
Codeg
CodeC
CodeCL-003
CodeBlack Pepper CO₂ (optional)
Code—
Code1 drop
CodeC
CodePR-001
CodeCosgard 221
CodeAromantic
Code0.70
Codeg
CodeC
3. MANUFACTURING WORKFLOW
Step
1
2
3
4
5
6
7
8
9
10
11
Prepared according to the Lanette protocol described in the magistral fiche.
| Action |
|---|
| ✓ |
| Verify raw materials |
| □ |
| Prepare water phase |
| □ |
| Prepare lipid/dispersion phase |
| □ |
| Pre-disperse PEA and Boswellia |
| □ |
| Emulsification |
| □ |
| Cool below 40°C |
| □ |
| Add botanical extracts |
| □ |
| Add Silicea Gel (+1 drop Silicea D8) |
| □ |
| Quality Control |
| □ |
| Fill into airless dispensers |
| □ |
| Batch Release |
| □ |
Action✓
ActionVerify raw materials
Action□
ActionPrepare water phase
Action□
ActionPrepare lipid/dispersion phase
Action□
ActionPre-disperse PEA and Boswellia
Action□
ActionEmulsification
Action□
ActionCool below 40°C
Action□
ActionAdd botanical extracts
Action□
ActionAdd Silicea Gel (+1 drop Silicea D8)
Action□
ActionQuality Control
Action□
ActionFill into airless dispensers
Action□
ActionBatch Release
Action□
4. QUALITY CONTROL
Standard SQMS Quality Control
Appearance
Colour
Odour
Homogeneity
pH (5.2–5.5)
Viscosity
Packaging
Net Weight
5. BATCH RELEASE
Standard SQMS Batch Release
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Posterior Zone
Additional Posterior Zone
Frequency
Treatment Phase
Clinical zones and EMG targets are based on the magistral fiche.
| Value |
|---|
| L2–L4 |
| Inguinal region |
| ASIS projection |
| Femoral triangle |
| Paravertebral L2–L4 |
| Quadratus lumborum & posterior iliac crest |
| 1–2× daily |
| Weeks 1–2 |
ValueL2–L4
ValueInguinal region
ValueASIS projection
ValueFemoral triangle
ValueParavertebral L2–L4
ValueQuadratus lumborum & posterior iliac crest
Value1–2× daily
ValueWeeks 1–2
Related documents
Platform modules